利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1615 条记录 (耗时 0.033 秒)

    USE OF HLA-A*11:01-RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES FOR IDENTIFYING HBV-SPECIFIC CD8+ T CELLS
    1.
    发明申请
    USE OF HLA-A*11:01-RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES FOR IDENTIFYING HBV-SPECIFIC CD8+ T CELLS 有权

    公开(公告)号：US20230087348A1

    公开(公告)日：2023-03-23

    申请号：US17421816

    申请日：2020-01-13

    申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

    发明人： Yang CHENG ,  Evan NEWELL

    IPC分类号： A61K35/17 ,  A61K39/29 ,  C12N15/86

    摘要： The present invention relates to peptides and their ability to identify and bind to T cells specific for HBV-infected hepa-tocytes. In an first aspect of the invention, there is provided a peptide comprising an amino sequence selected from the group consisting of STLPETAVVRR, STLPETAVVR, STLPETTVVRR, STLPETTVIRR, STPPETTVVRR, STLPETTVVGR and STIPETTVVRR, wherein the peptide is derived from Hepatitis B virus core169 and is capable of binding HLA-A*1101 and when bound to HLA-A*1101 s capable of identifying T cells specific for Hepatitis B virus. In a second aspect of the invention, there is provided A T cell expressing a T cell receptor (TCR) molecule, wherein the TCR molecule comprises an amino acid sequence selected from the group comprising: CASGDSNSPLHF, CASSGGQIVYEQYF, CSARGGRGGDYTF and CASSQDWTEAFF, the T cell receptor is able to bind to a pep-tide according to the first aspect of the invention.

    COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HEPATITIS B AND D
    2.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HEPATITIS B AND D 有权

    公开(公告)号：US20230079898A1

    公开(公告)日：2023-03-16

    申请号：US17794786

    申请日：2021-01-26

    申请人： Svenska Vaccinfabriken Produktion AB

    发明人： Matti Sällberg ,  Lars Frelin

    IPC分类号： A61K39/29 ,  A61P31/14 ,  A61P31/20

    摘要： Disclosed herein are immunogenic compositions or product combinations of engineered hepatitis B and hepatitis D nucleic acids, genes, peptides, or proteins that can be used to illicit an immune response against a hepatitis B and/or hepatitis D infection. Also disclosed are methods of using the immunogenic compositions or product combinations in subjects to generate immune responses against HBV and/or HDV by administering the compositions or combinations with a nucleic acid prime and polypeptide boost approach.

    Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR)
    3.
    发明授权
    Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR) 有权

    公开(公告)号：US11576932B2

    公开(公告)日：2023-02-14

    申请号：US16089809

    申请日：2016-03-31

    申请人： Lion TCR Pte. Ltd.

    发明人： Antonio Bertoletti ,  Sarene Koh

    IPC分类号： A61K35/17 ,  C07K14/70 ,  C12N5/0783 ,  C07K14/725 ,  A61P31/20 ,  A61K39/29 ,  C07K14/02

    摘要： The present invention relates to T cells, in particular a non-activated T cell, comprising an exogenous nucleic acid encoding a T cell Receptor (TCR) specific for a virus. An embodiment of the invention is directed to a non-activated (resting) T cell expressing Hepatitis B virus (HBV) envelope s183-191 TCR capable of inhibiting viral replication and which shows reduced expression of perforins and/or granzymes in response to stimulation as compared to an activated T cell expressing the said TCR. Also encompassed are methods for producing such cells, compositions, pharmaceutical compositions and kits comprising such cells and medical uses thereof.